Merck's antipsychotic Saphris is tied to hypersensitivity, FDA says

09/1/2011 | Medscape (free registration)

Merck & Co.'s atypical antipsychotic Saphris, or asenapine maleate, is associated with serious allergic reactions, including angioedema and anaphylaxis, according to an FDA alert. The agency's Adverse Event Reporting System lists 52 hypersensitivity cases among Saphris users, with some reactions occurring simultaneously or after the first dose.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI